Featured Articles
-
Demystifying AI Governance: A Strategic Approach For Life Sciences
5/17/2024
As AI models become more deeply embedded across functions at biopharmaceutical companies, it is crucial to effectively manage the associated risks of data privacy and security, bias and fairness, regulatory compliance, and reliability and performance.
-
Drug Discovery And Development, Powered By Physician Intelligence
5/15/2024
For Nuvalent CEO James Porter, physician intelligence is more important than artificial intelligence in discovering and developing new therapies that tackle key unmet needs among cancer patients.
-
Ensuring Security And Privacy In Life Sciences Master Data Governance
5/10/2024
High-quality and secure data is the lifeblood of biopharmaceutical innovation and organizational success. Ravikumar Vallepu offers best practices for master data governance plans, and how to cultivate a data-centric culture.
-
The Power of Putting People First in Driving Business Growth
5/7/2024
Happy workers drive high performing businesses. Biopharma executive John Harlow shares five tips for adopting a people-first mindset and other strategies for meaningful engagement with colleagues.
-
Pricing For Rare Disease Therapies And Cures: What’s Fair?
5/6/2024
What is a "fair" price for a curative rare disease therapy, or an effective but chronic rare disease therapy? Charles River Associates surveyed U.S. payers, before and after COVID, to find out.
-
Meaningful Industry Change Means Balancing Tech And Human Touch
5/6/2024
Technology and AI/ML are advancing at an unprecedented pace, and we must not lose sight of our industry's core: human-to-human interaction.
-
Building On Direct-To-Patient Marketing For Improved Access To Therapeutics
5/2/2024
PA Consulting identifies the top three questions that biopharmaceutical companies should consider before launching a direct-to-patient platform and service offering.
-
Where Are They Now? SQZ Biotech
5/1/2024
SQZ Biotech, a novel cell therapy company with Big Pharma backing, is no more. However, the company's science, and its founding CEO, will continue on under new auspices.
-
Take-Home Microdosing Trial Studies Sub-Hallucinogenic For Depression
4/30/2024
MindBio Therapeutics CEO Justin Hanka details the company’s Phase 2a clinical trial investigating the use of a take-home microdosing regimen for depression.
-
Reviva Pharma’s Novel Funding Approach In Schizophrenia
4/25/2024
Reviva Pharma CEO Laxminarayan Bhat, Ph.D. found a novel way to build an investor base for his company during a time when Big Pharma was exiting complicated CNS diseases. Now, Reviva has a late-stage schizophrenia candidate just as CNS is back in vogue.